Research programme: cancer therapeutics - Endo/Aurigene
Latest Information Update: 16 Jul 2016
At a glance
- Originator Aurigene Discovery Technologies
- Developer Aurigene Discovery Technologies; Endo Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in India
- 22 Apr 2013 Early research in Cancer in India (unspecified route)
- 26 Mar 2012 No development reported for Cancer in India (unspecified route)